EP1977234A4 - Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung - Google Patents

Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung

Info

Publication number
EP1977234A4
EP1977234A4 EP20070756361 EP07756361A EP1977234A4 EP 1977234 A4 EP1977234 A4 EP 1977234A4 EP 20070756361 EP20070756361 EP 20070756361 EP 07756361 A EP07756361 A EP 07756361A EP 1977234 A4 EP1977234 A4 EP 1977234A4
Authority
EP
European Patent Office
Prior art keywords
collagen
type
lung
sample
connective tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20070756361
Other languages
German (de)
French (fr)
Other versions
EP1977234A1 (en
EP1977234B1 (en
Inventor
David S Wilkes
Michael J Klemsz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Priority to EP13175642.1A priority Critical patent/EP2672266B1/en
Publication of EP1977234A1 publication Critical patent/EP1977234A1/en
Publication of EP1977234A4 publication Critical patent/EP1977234A4/en
Application granted granted Critical
Publication of EP1977234B1 publication Critical patent/EP1977234B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Abstract

Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen.
EP07756361.7A 2006-01-13 2007-01-13 Type V collagen for use in a method of treatment of idiopathic pulmonary fibrosis Active EP1977234B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13175642.1A EP2672266B1 (en) 2006-01-13 2007-01-13 Method for screening a lung transplant candidate for an elevated risk of rejection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75919506P 2006-01-13 2006-01-13
PCT/US2007/060533 WO2007120947A1 (en) 2006-01-13 2007-01-13 Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP13175642.1A Division EP2672266B1 (en) 2006-01-13 2007-01-13 Method for screening a lung transplant candidate for an elevated risk of rejection
EP13175642.1A Division-Into EP2672266B1 (en) 2006-01-13 2007-01-13 Method for screening a lung transplant candidate for an elevated risk of rejection

Publications (3)

Publication Number Publication Date
EP1977234A1 EP1977234A1 (en) 2008-10-08
EP1977234A4 true EP1977234A4 (en) 2009-06-03
EP1977234B1 EP1977234B1 (en) 2015-11-04

Family

ID=38609836

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07756361.7A Active EP1977234B1 (en) 2006-01-13 2007-01-13 Type V collagen for use in a method of treatment of idiopathic pulmonary fibrosis
EP13175642.1A Not-in-force EP2672266B1 (en) 2006-01-13 2007-01-13 Method for screening a lung transplant candidate for an elevated risk of rejection

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP13175642.1A Not-in-force EP2672266B1 (en) 2006-01-13 2007-01-13 Method for screening a lung transplant candidate for an elevated risk of rejection

Country Status (9)

Country Link
US (3) US7759075B2 (en)
EP (2) EP1977234B1 (en)
JP (2) JP5030973B2 (en)
CN (1) CN101375157B (en)
AU (1) AU2007238533C1 (en)
BR (1) BRPI0706575B8 (en)
CA (2) CA2641318C (en)
HK (1) HK1126861A1 (en)
WO (1) WO2007120947A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5030973B2 (en) * 2006-01-13 2012-09-19 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション Method for determining whether an IPF (idiopathic pulmonary fibrosis) patient is a candidate for oral tolerance treatment with type V collagen
EP3536325A1 (en) * 2006-11-28 2019-09-11 University Of Southern California Method for promoting wound healing
JP2012518001A (en) * 2009-02-13 2012-08-09 インディアナ ユニバーシティ リサーチ アンド テクノロジー コーポレイション Compounds and methods for inhibiting MMP2 and MMP9
WO2010124058A1 (en) * 2009-04-22 2010-10-28 Indiana University Research And Technology Corporation Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma
CN102712954A (en) 2009-11-06 2012-10-03 小利兰·斯坦福大学托管委员会 Non-invasive diagnosis of graft rejection in organ transplant patients
CA2856798A1 (en) * 2011-05-31 2012-12-06 Idexx Laboratories, Inc. Detection of degradation products of feline nt-probnp
SG11201405830VA (en) * 2012-03-27 2014-10-30 Genentech Inc Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
JP6058354B2 (en) * 2012-11-02 2017-01-11 東芝メディカルシステムズ株式会社 Image processing apparatus and image processing method
JP6312054B2 (en) * 2013-11-06 2018-04-18 学校法人日本大学 Biomarker for interstitial pneumonia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
CA2055813A1 (en) 1990-11-20 1992-05-21 Dariush Davalian Cyclosporin immunoassay
US6911220B1 (en) 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
JP2702354B2 (en) * 1992-05-11 1998-01-21 帝人株式会社 Marker of lung tissue damage in blood
US5778875A (en) * 1996-05-06 1998-07-14 U.S. Divers Co., Inc. First stage regulator and rotatable in-line valve
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
US5962025A (en) 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases
US5990274A (en) 1997-11-25 1999-11-23 Dade Behring Inc. Cyclosporine derivatives and uses thereof
UA74141C2 (en) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants)
CA2398467C (en) * 2000-01-31 2010-06-29 Asahi Kasei Kabushiki Kaisha Antibody for detecting chlamydia pneumoniae
US7348005B2 (en) 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
PL358132A1 (en) * 2000-03-23 2004-08-09 Akzo Nobel N.V. Use of mia in immunotherapy
JP2002220343A (en) * 2001-01-26 2002-08-09 Toray Ind Inc Life prolongation agent for diffuse lung disease
CN1961214A (en) * 2004-04-08 2007-05-09 詹森药业有限公司 Method for immunohistochemical detection of collagen in a tissue sample
JP2009515983A (en) 2005-11-16 2009-04-16 ザ ユニバーシティー オブ テネシー リサーチ ファウンデーション Method for the treatment of fibrotic diseases by induction of immune tolerance
JP5030973B2 (en) 2006-01-13 2012-09-19 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション Method for determining whether an IPF (idiopathic pulmonary fibrosis) patient is a candidate for oral tolerance treatment with type V collagen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K. YASUFUKU ET AL: "Oral tolerance induction by type V collagen downregulates lung allograft rejection.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY JUL 2001, vol. 25, no. 1, July 2001 (2001-07-01), Palo Alto, CA USA, pages 26 - 34, XP002523627, ISSN: 1044-1549 *
See also references of WO2007120947A1 *

Also Published As

Publication number Publication date
CA2641318A1 (en) 2007-10-25
US7759075B2 (en) 2010-07-20
US7939281B2 (en) 2011-05-10
JP5936349B2 (en) 2016-06-22
HK1126861A1 (en) 2009-09-11
CN101375157A (en) 2009-02-25
CA2965211C (en) 2020-06-30
BRPI0706575A2 (en) 2011-04-05
EP1977234A1 (en) 2008-10-08
AU2007238533C1 (en) 2013-08-15
BRPI0706575B8 (en) 2021-05-25
US8039225B2 (en) 2011-10-18
JP2009524023A (en) 2009-06-25
CA2965211A1 (en) 2007-10-25
BRPI0706575B1 (en) 2018-12-11
EP2672266A2 (en) 2013-12-11
CA2641318C (en) 2017-06-20
EP2672266B1 (en) 2018-08-01
WO2007120947A1 (en) 2007-10-25
AU2007238533B2 (en) 2012-09-20
JP2012108137A (en) 2012-06-07
CN101375157B (en) 2015-06-17
US20110020838A1 (en) 2011-01-27
EP2672266A3 (en) 2014-02-05
JP5030973B2 (en) 2012-09-19
US20090017013A1 (en) 2009-01-15
US20110183356A1 (en) 2011-07-28
AU2007238533A1 (en) 2007-10-25
EP1977234B1 (en) 2015-11-04

Similar Documents

Publication Publication Date Title
EP1977234A4 (en) Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung
JP7344801B2 (en) Glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) Methods to assist in diagnosis and assessment of injuries sustained or potential injuries
NO20072206L (en) Procedures for Investigating Alzheimer's Disease and Diagnostic Reagent
ATE535535T1 (en) METHODS FOR DIAGNOSING DEMENTIA AND OTHER NEUROLOGICAL DISEASES
HUP0202532A2 (en) Human monoclonal antibody against a costimulatory signal transduction molecule (ailim) and pharmaceutical use thereof
ATE502305T1 (en) USE OF PRECURSORS OF ENKEPHALINS AND/OR THEIR FRAGMENTS IN MEDICAL DIAGNOSTICS
JP2009515183A5 (en)
JP2008528974A5 (en)
RU2012120706A (en) DIAGNOSTIC AND THERAPEUTIC METHODS
Foley III et al. Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model
ATE483982T1 (en) CSF DIAGNOSTIC IN VITRO METHOD FOR DIAGNOSING DEMENTIA AND NEUROINFLAMMATORY DISEASES
NZ531712A (en) Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
RU2012121096A (en) MELANOMA BIOMARKER
ATE473448T1 (en) METHOD FOR DIAGNOSING CARDIOVASCULAR DISEASES
Veidal et al. Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers
KR20060006774A (en) Diagnosis of autism
ATE509270T1 (en) MICROPARTICLES OBTAINED FROM BLOOD PLATES AS NEW DIAGNOSTIC MARKERS FOR CARDIOVASCULAR DISEASE
EP2598875B1 (en) Biomechanical-based methods of diagnosing scoliosis
US20150252101A1 (en) Methods and Compositions for Biomarkers of Fatigue, Fitness and Physical Performance Capacity
CN105854015A (en) Anti-CCL2 antibodies for treatment of scleroderma
RU2015133019A (en) METHOD FOR PREDICING RISK OF CANCER DEVELOPMENT OR DIAGNOSTIC OF CANCER IN INDIVIDUAL
ATE511646T1 (en) DIAGNOSIS OF MYCOBACTERIAL INFECTIONS BY DETERMINING IFN-GAMMA
DE502004008729D1 (en) Antibodies directed against the prothrombin fragment F1 + 2, their preparation and use
CN105556306B (en) For monitoring the method and prognosis kit of multiple sclerosis (MS)
EP2839290A1 (en) Method for presymptomatic diagnosis of coeliac disease and gluten sensitivity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080812

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/567 20060101ALI20090423BHEP

Ipc: G01N 33/00 20060101AFI20071121BHEP

Ipc: G01N 33/566 20060101ALI20090423BHEP

Ipc: G01N 33/564 20060101ALI20090423BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090504

17Q First examination report despatched

Effective date: 20090720

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602007043773

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: G01N0033000000

Ipc: G01N0033680000

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/564 20060101ALI20120509BHEP

Ipc: G01N 33/68 20060101AFI20120509BHEP

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KLEMSZ, MICHAEL, J.

Inventor name: WILKES, DAVID, S.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150506

INTG Intention to grant announced

Effective date: 20150508

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 759571

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007043773

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20151104

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 759571

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160304

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160304

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007043773

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160113

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

26N No opposition filed

Effective date: 20160805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160113

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Effective date: 20170329

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070113

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151104

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230125

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230127

Year of fee payment: 17

Ref country code: DE

Payment date: 20230127

Year of fee payment: 17

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526